This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1988 Dec;15(6):396-420.

doi: 10.2165/00003088-198815060-00004.

Guide to drug dosage in hepatic disease

N M Bass¹, R L Williams

Affiliations

PMID: 3072141
DOI: 10.2165/00003088-198815060-00004

Review

Guide to drug dosage in hepatic disease

N M Bass et al. Clin Pharmacokinet. 1988 Dec.

. 1988 Dec;15(6):396-420.

doi: 10.2165/00003088-198815060-00004.

Authors

N M Bass¹, R L Williams

Affiliation

¹ Department of Medicine, University of California, San Francisco.

PMID: 3072141
DOI: 10.2165/00003088-198815060-00004

No abstract available

PubMed Disclaimer

Similar articles

Hepatic clearance measurements and pharmacokinetics.
Keiding S, Andreasen PB. Keiding S, et al. Pharmacology. 1979;19(3):105-10. doi: 10.1159/000137296. Pharmacology. 1979. PMID: 392549 Review.
Is drug administration in hepatic disease really so complicated?
[No authors listed] [No authors listed] N Engl J Med. 1984 May 17;310(20):1331-2. doi: 10.1056/nejm198405173102019. N Engl J Med. 1984. PMID: 6717501 No abstract available.
Drug pharmacokinetics in cardiac and hepatic disease.
Williams RL, Benet LZ. Williams RL, et al. Annu Rev Pharmacol Toxicol. 1980;20:389-413. doi: 10.1146/annurev.pa.20.040180.002133. Annu Rev Pharmacol Toxicol. 1980. PMID: 6992701 Review. No abstract available.
[Dosage of drugs with regard to their distribution volume and biological half-life].
Dahl SG. Dahl SG. Tidsskr Nor Laegeforen. 1974 Jun 30;94(18):1201-2. Tidsskr Nor Laegeforen. 1974. PMID: 4839999 Norwegian. No abstract available.
Clinical pharmacokinetics.
Atkinson AJ Jr, Kushner W. Atkinson AJ Jr, et al. Annu Rev Pharmacol Toxicol. 1979;19:105-27. doi: 10.1146/annurev.pa.19.040179.000541. Annu Rev Pharmacol Toxicol. 1979. PMID: 378099 Review. No abstract available.

See all similar articles

Cited by

A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.
Steelandt J, Jean-Bart E, Goutelle S, Tod M. Steelandt J, et al. Clin Pharmacokinet. 2015 Dec;54(12):1245-58. doi: 10.1007/s40262-015-0288-9. Clin Pharmacokinet. 2015. PMID: 26070946
Dose adaptation of antineoplastic drugs in patients with liver disease.
Tchambaz L, Schlatter C, Jakob M, Krähenbühl A, Wolf P, Krähenbühl S. Tchambaz L, et al. Drug Saf. 2006;29(6):509-22. doi: 10.2165/00002018-200629060-00004. Drug Saf. 2006. PMID: 16752933 Review.
Clinical pharmacokinetics of newer antibacterial agents in liver disease.
Westphal JF, Brogard JM. Westphal JF, et al. Clin Pharmacokinet. 1993 Jan;24(1):46-58. doi: 10.2165/00003088-199324010-00004. Clin Pharmacokinet. 1993. PMID: 8448972 Review.
Role of viral infections in the induction of adverse drug reactions.
Levy M. Levy M. Drug Saf. 1997 Jan;16(1):1-8. doi: 10.2165/00002018-199716010-00001. Drug Saf. 1997. PMID: 9010640 Review.
Effects of liver disease on pharmacokinetics. An update.
Rodighiero V. Rodighiero V. Clin Pharmacokinet. 1999 Nov;37(5):399-431. doi: 10.2165/00003088-199937050-00004. Clin Pharmacokinet. 1999. PMID: 10589374 Review.

See all "Cited by" articles

References

1. Clin Pharmacol Ther. 1976 Jul;20(1):90-7 - PubMed
1. J Antimicrob Chemother. 1985 Mar;15(3):365-74 - PubMed
1. Clin Pharmacol Ther. 1984 Jun;35(6):831-7 - PubMed
1. Eur J Clin Pharmacol. 1980 Apr;17(4):275-84 - PubMed
1. Br J Anaesth. 1980 Aug;52(8):789-94 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information